Buscar
Mostrando ítems 21-30 de 62
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
(Wiley-Blackwell, 2014-01-01)
BackgroundMucopolysaccharidosis II, also known as Hunter syndrome, is a rare, X-linked disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase, which catalyses a step in the catabolism of glycosaminoglycans. ...
Nano carriers for nitric oxide delivery and its potential applications in plant physiological process: A mini review
(Springer, 2014-01-01)
Nitric oxide (NO) plays a key role in plant growth and defense. Since NO is a small molecule, devoid of charge and relatively lipophilic, it easily crosses cell membranes, acting as an important signaling messenger. Recently, ...
The multitude of targets for the immune system and drug therapy in the fungal cell wall
(Elsevier B.V., 2005-04-01)
Recent studies on fungi revealed that several cytosolic and membrane components migrate to the cell wall together with secreted proteins and biosynthetic polysaccharides to build a dynamic immunoreactive structure. New ...
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
(Expert Reviews, 2010-01-01)
Pseudomonas aeruginosa and Acinetobacter baumannii are major nosocomial pathogens worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to virtually any antimicrobial agent. An increasing ...
Photodynamic inactivation of biofilm: Taking a lightly colored approach to stubborn infection
(2013-07-01)
Microbial biofilms are responsible for a variety of microbial infections in different parts of the body, such as urinary tract infections, catheter infections, middle-ear infections, gingivitis, caries, periodontitis, ...
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
(Wiley-Blackwell, 2013-01-01)
BackgroundAn estimated 220,000 new cases of non-small cell lung cancer (NSCLC) and 160,000 deaths are expected to occur in the US in 2013, representing about 28% of cancer-related mortality. Approximately 75% of these ...
Future Direction in Pharmacotherapy for Non-neurogenic Male Lower Urinary Tract Symptoms
(Elsevier B.V., 2013-10-01)
Background: the pathophysiology of male lower urinary tract symptoms (LUTS) is highly complex and multifactorial. the shift in perception that LUTS are not sex or organ specific has not been followed by significant innovations ...
An update on the pharmacogenetics of treating hypertension
(Nature Publishing Group, 2015)
Retinal and Ocular Toxicity in Ocular Application of Drugs and Chemicals - Part I: Animal Models and Toxicity Assays
(Karger, 2010-01-01)
Aims: Experimental retinal research has gained great importance due to the ophthalmic pharmacotherapy era. An increasing number of drugs are constantly released into the market for the treatment of retinal diseases. in ...
Botulinum toxin for myofascial pain syndromes in adults
(Wiley-Blackwell, 2014-01-01)
BackgroundThis is an updated version of the original Cochrane review published in Issue 4, 2012. Myofascial pain syndrome (MPS) is a regional muscular pain syndrome characterised by the presence of trigger points, which ...